The Experts below are selected from a list of 51 Experts worldwide ranked by ideXlab platform
B Anderson - One of the best experts on this subject based on the ideXlab platform.
-
randomized trial of cisplatin versus cisplatin plus Mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix a gynecologic oncology group study
Journal of Clinical Oncology, 1997Co-Authors: George A. Omura, J A Blessing, L Vaccarello, M L Berman, D L Clarkepearson, David G Mutch, B AndersonAbstract:PURPOSECisplatin, Mitolactol (dibromodulcitol), and ifosfamide have been the most active single agents in squamous carcinoma of the cervix identified so far by the Gynecologic Oncology Group (GOG). Combinations of cisplatin plus ifosfamide and cisplatin plus Mitolactol are prospectively compared with cisplatin alone.PATIENTS AND METHODSPatients were randomized to receive cisplatin 50 mg/m2 or the same dose of cisplatin plus Mitolactol (C + M) 180 mg/m2 orally on days 2 to 6, or cisplatin plus ifosfamide (CIFX) 5 g/m2 given as a 24-hour infusion plus mesna 6 g/m2 during and for 12 hours after the ifosfamide infusion, every 3 weeks for up to six courses. Of 454 patients entered, 438 were eligible and analyzed for response and survival.RESULTSCIFX had a higher response rate (31.1% v 17.8%, p = .004) and longer progression-free survival (PFS) time (P = .003) compared with cisplatin alone. The median times to progression or death were 4.6 and 3.2 months, respectively. C + M showed no significant improvement in...
-
Randomized trial of cisplatin versus cisplatin plus Mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997Co-Authors: George A. Omura, J A Blessing, L Vaccarello, M L Berman, David G Mutch, D. L. Clarke-pearson, B AndersonAbstract:Cisplatin, Mitolactol (dibromodulcitol), and ifosfamide have been the most active single agents in squamous carcinoma of the cervix identified so far by the Gynecologic Oncology Group (GOG). Combinations of cisplatin plus ifosfamide and cisplatin plus Mitolactol are prospectively compared with cisplatin alone. Patients were randomized to receive cisplatin 50 mg/m2 or the same dose of cisplatin plus Mitolactol (C + M) 180 mg/m2 orally on days 2 to 6, or cisplatin plus ifosfamide (CIFX) 5 g/m2 given as a 24-hour infusion plus mesna 6 g/m2 during and for 12 hours after the ifosfamide infusion, every 3 weeks for up to six courses. Of 454 patients entered, 438 were eligible and analyzed for response and survival. CIFX had a higher response rate (31.1% v 17.8%, p = .004) and longer progression-free survival (PFS) time (P = .003) compared with cisplatin alone. The median times to progression or death were 4.6 and 3.2 months, respectively. C + M showed no significant improvement in these parameters compared with cisplatin alone. Survival was associated with initial performance score (PS; 0 was more favorable; P < .001) and with age (younger was unfavorable, P = .025). There was no significant difference in overall survival between cisplatin and either of the combinations. Leukopenia, renal toxicity, peripheral neurotoxicity, and CNS toxicity were more frequent with CIFX (P < .05). CIFX improved the response rate and PFS duration in advanced cervix cancer compared with cisplatin alone, but at the cost of greater toxicity and with no improvement in survival.
George A. Omura - One of the best experts on this subject based on the ideXlab platform.
-
Randomized trial of cisplatin versus cisplatin plus Mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997Co-Authors: George A. Omura, J A Blessing, L Vaccarello, M L Berman, David G Mutch, D. L. Clarke-pearson, B AndersonAbstract:Cisplatin, Mitolactol (dibromodulcitol), and ifosfamide have been the most active single agents in squamous carcinoma of the cervix identified so far by the Gynecologic Oncology Group (GOG). Combinations of cisplatin plus ifosfamide and cisplatin plus Mitolactol are prospectively compared with cisplatin alone. Patients were randomized to receive cisplatin 50 mg/m2 or the same dose of cisplatin plus Mitolactol (C + M) 180 mg/m2 orally on days 2 to 6, or cisplatin plus ifosfamide (CIFX) 5 g/m2 given as a 24-hour infusion plus mesna 6 g/m2 during and for 12 hours after the ifosfamide infusion, every 3 weeks for up to six courses. Of 454 patients entered, 438 were eligible and analyzed for response and survival. CIFX had a higher response rate (31.1% v 17.8%, p = .004) and longer progression-free survival (PFS) time (P = .003) compared with cisplatin alone. The median times to progression or death were 4.6 and 3.2 months, respectively. C + M showed no significant improvement in these parameters compared with cisplatin alone. Survival was associated with initial performance score (PS; 0 was more favorable; P < .001) and with age (younger was unfavorable, P = .025). There was no significant difference in overall survival between cisplatin and either of the combinations. Leukopenia, renal toxicity, peripheral neurotoxicity, and CNS toxicity were more frequent with CIFX (P < .05). CIFX improved the response rate and PFS duration in advanced cervix cancer compared with cisplatin alone, but at the cost of greater toxicity and with no improvement in survival.
-
randomized trial of cisplatin versus cisplatin plus Mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix a gynecologic oncology group study
Journal of Clinical Oncology, 1997Co-Authors: George A. Omura, J A Blessing, L Vaccarello, M L Berman, D L Clarkepearson, David G Mutch, B AndersonAbstract:PURPOSECisplatin, Mitolactol (dibromodulcitol), and ifosfamide have been the most active single agents in squamous carcinoma of the cervix identified so far by the Gynecologic Oncology Group (GOG). Combinations of cisplatin plus ifosfamide and cisplatin plus Mitolactol are prospectively compared with cisplatin alone.PATIENTS AND METHODSPatients were randomized to receive cisplatin 50 mg/m2 or the same dose of cisplatin plus Mitolactol (C + M) 180 mg/m2 orally on days 2 to 6, or cisplatin plus ifosfamide (CIFX) 5 g/m2 given as a 24-hour infusion plus mesna 6 g/m2 during and for 12 hours after the ifosfamide infusion, every 3 weeks for up to six courses. Of 454 patients entered, 438 were eligible and analyzed for response and survival.RESULTSCIFX had a higher response rate (31.1% v 17.8%, p = .004) and longer progression-free survival (PFS) time (P = .003) compared with cisplatin alone. The median times to progression or death were 4.6 and 3.2 months, respectively. C + M showed no significant improvement in...
-
Chemotherapy of cervix cancer with Mitolactol (dibromodulcitol, NSC 104800) and cisplatin. A phase I study of the Gynecologic Oncology Group.
American journal of clinical oncology, 1992Co-Authors: George A. Omura, Judith L. Hubbard, Kenneth D. Hatch, John B. Schlaerth, John A. BlessingAbstract:In this Phase I study, thirteen women with advanced cervix cancer were treated with Mitolactol (dibromodulcitol) plus cisplatin to determine a maximum tolerable dose schedule. Response was not an objective of this study, but four partial responses were seen in nine patients with measurable lesions. In general, the therapy was well tolerated, but of the ten patients treated at the first dose level (cisplatin 50 mg/m2 intravenously on day 1 plus Mitolactol 180 mg/m2 orally on days 2-6 every 3-4 weeks), 5 required de-escalations and 8 required delays because of toxicity. All three patients treated with cisplatin plus a higher dose of Mitolactol (270 mg/m2 x 5) required dose reductions and delays for hematologic toxicity. The first dose level appears tolerable by patients with, and promising in treating, advanced cervix cancer.
L Vaccarello - One of the best experts on this subject based on the ideXlab platform.
-
randomized trial of cisplatin versus cisplatin plus Mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix a gynecologic oncology group study
Journal of Clinical Oncology, 1997Co-Authors: George A. Omura, J A Blessing, L Vaccarello, M L Berman, D L Clarkepearson, David G Mutch, B AndersonAbstract:PURPOSECisplatin, Mitolactol (dibromodulcitol), and ifosfamide have been the most active single agents in squamous carcinoma of the cervix identified so far by the Gynecologic Oncology Group (GOG). Combinations of cisplatin plus ifosfamide and cisplatin plus Mitolactol are prospectively compared with cisplatin alone.PATIENTS AND METHODSPatients were randomized to receive cisplatin 50 mg/m2 or the same dose of cisplatin plus Mitolactol (C + M) 180 mg/m2 orally on days 2 to 6, or cisplatin plus ifosfamide (CIFX) 5 g/m2 given as a 24-hour infusion plus mesna 6 g/m2 during and for 12 hours after the ifosfamide infusion, every 3 weeks for up to six courses. Of 454 patients entered, 438 were eligible and analyzed for response and survival.RESULTSCIFX had a higher response rate (31.1% v 17.8%, p = .004) and longer progression-free survival (PFS) time (P = .003) compared with cisplatin alone. The median times to progression or death were 4.6 and 3.2 months, respectively. C + M showed no significant improvement in...
-
Randomized trial of cisplatin versus cisplatin plus Mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997Co-Authors: George A. Omura, J A Blessing, L Vaccarello, M L Berman, David G Mutch, D. L. Clarke-pearson, B AndersonAbstract:Cisplatin, Mitolactol (dibromodulcitol), and ifosfamide have been the most active single agents in squamous carcinoma of the cervix identified so far by the Gynecologic Oncology Group (GOG). Combinations of cisplatin plus ifosfamide and cisplatin plus Mitolactol are prospectively compared with cisplatin alone. Patients were randomized to receive cisplatin 50 mg/m2 or the same dose of cisplatin plus Mitolactol (C + M) 180 mg/m2 orally on days 2 to 6, or cisplatin plus ifosfamide (CIFX) 5 g/m2 given as a 24-hour infusion plus mesna 6 g/m2 during and for 12 hours after the ifosfamide infusion, every 3 weeks for up to six courses. Of 454 patients entered, 438 were eligible and analyzed for response and survival. CIFX had a higher response rate (31.1% v 17.8%, p = .004) and longer progression-free survival (PFS) time (P = .003) compared with cisplatin alone. The median times to progression or death were 4.6 and 3.2 months, respectively. C + M showed no significant improvement in these parameters compared with cisplatin alone. Survival was associated with initial performance score (PS; 0 was more favorable; P < .001) and with age (younger was unfavorable, P = .025). There was no significant difference in overall survival between cisplatin and either of the combinations. Leukopenia, renal toxicity, peripheral neurotoxicity, and CNS toxicity were more frequent with CIFX (P < .05). CIFX improved the response rate and PFS duration in advanced cervix cancer compared with cisplatin alone, but at the cost of greater toxicity and with no improvement in survival.
M L Berman - One of the best experts on this subject based on the ideXlab platform.
-
randomized trial of cisplatin versus cisplatin plus Mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix a gynecologic oncology group study
Journal of Clinical Oncology, 1997Co-Authors: George A. Omura, J A Blessing, L Vaccarello, M L Berman, D L Clarkepearson, David G Mutch, B AndersonAbstract:PURPOSECisplatin, Mitolactol (dibromodulcitol), and ifosfamide have been the most active single agents in squamous carcinoma of the cervix identified so far by the Gynecologic Oncology Group (GOG). Combinations of cisplatin plus ifosfamide and cisplatin plus Mitolactol are prospectively compared with cisplatin alone.PATIENTS AND METHODSPatients were randomized to receive cisplatin 50 mg/m2 or the same dose of cisplatin plus Mitolactol (C + M) 180 mg/m2 orally on days 2 to 6, or cisplatin plus ifosfamide (CIFX) 5 g/m2 given as a 24-hour infusion plus mesna 6 g/m2 during and for 12 hours after the ifosfamide infusion, every 3 weeks for up to six courses. Of 454 patients entered, 438 were eligible and analyzed for response and survival.RESULTSCIFX had a higher response rate (31.1% v 17.8%, p = .004) and longer progression-free survival (PFS) time (P = .003) compared with cisplatin alone. The median times to progression or death were 4.6 and 3.2 months, respectively. C + M showed no significant improvement in...
-
Randomized trial of cisplatin versus cisplatin plus Mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997Co-Authors: George A. Omura, J A Blessing, L Vaccarello, M L Berman, David G Mutch, D. L. Clarke-pearson, B AndersonAbstract:Cisplatin, Mitolactol (dibromodulcitol), and ifosfamide have been the most active single agents in squamous carcinoma of the cervix identified so far by the Gynecologic Oncology Group (GOG). Combinations of cisplatin plus ifosfamide and cisplatin plus Mitolactol are prospectively compared with cisplatin alone. Patients were randomized to receive cisplatin 50 mg/m2 or the same dose of cisplatin plus Mitolactol (C + M) 180 mg/m2 orally on days 2 to 6, or cisplatin plus ifosfamide (CIFX) 5 g/m2 given as a 24-hour infusion plus mesna 6 g/m2 during and for 12 hours after the ifosfamide infusion, every 3 weeks for up to six courses. Of 454 patients entered, 438 were eligible and analyzed for response and survival. CIFX had a higher response rate (31.1% v 17.8%, p = .004) and longer progression-free survival (PFS) time (P = .003) compared with cisplatin alone. The median times to progression or death were 4.6 and 3.2 months, respectively. C + M showed no significant improvement in these parameters compared with cisplatin alone. Survival was associated with initial performance score (PS; 0 was more favorable; P < .001) and with age (younger was unfavorable, P = .025). There was no significant difference in overall survival between cisplatin and either of the combinations. Leukopenia, renal toxicity, peripheral neurotoxicity, and CNS toxicity were more frequent with CIFX (P < .05). CIFX improved the response rate and PFS duration in advanced cervix cancer compared with cisplatin alone, but at the cost of greater toxicity and with no improvement in survival.
David G Mutch - One of the best experts on this subject based on the ideXlab platform.
-
randomized trial of cisplatin versus cisplatin plus Mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix a gynecologic oncology group study
Journal of Clinical Oncology, 1997Co-Authors: George A. Omura, J A Blessing, L Vaccarello, M L Berman, D L Clarkepearson, David G Mutch, B AndersonAbstract:PURPOSECisplatin, Mitolactol (dibromodulcitol), and ifosfamide have been the most active single agents in squamous carcinoma of the cervix identified so far by the Gynecologic Oncology Group (GOG). Combinations of cisplatin plus ifosfamide and cisplatin plus Mitolactol are prospectively compared with cisplatin alone.PATIENTS AND METHODSPatients were randomized to receive cisplatin 50 mg/m2 or the same dose of cisplatin plus Mitolactol (C + M) 180 mg/m2 orally on days 2 to 6, or cisplatin plus ifosfamide (CIFX) 5 g/m2 given as a 24-hour infusion plus mesna 6 g/m2 during and for 12 hours after the ifosfamide infusion, every 3 weeks for up to six courses. Of 454 patients entered, 438 were eligible and analyzed for response and survival.RESULTSCIFX had a higher response rate (31.1% v 17.8%, p = .004) and longer progression-free survival (PFS) time (P = .003) compared with cisplatin alone. The median times to progression or death were 4.6 and 3.2 months, respectively. C + M showed no significant improvement in...
-
Randomized trial of cisplatin versus cisplatin plus Mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997Co-Authors: George A. Omura, J A Blessing, L Vaccarello, M L Berman, David G Mutch, D. L. Clarke-pearson, B AndersonAbstract:Cisplatin, Mitolactol (dibromodulcitol), and ifosfamide have been the most active single agents in squamous carcinoma of the cervix identified so far by the Gynecologic Oncology Group (GOG). Combinations of cisplatin plus ifosfamide and cisplatin plus Mitolactol are prospectively compared with cisplatin alone. Patients were randomized to receive cisplatin 50 mg/m2 or the same dose of cisplatin plus Mitolactol (C + M) 180 mg/m2 orally on days 2 to 6, or cisplatin plus ifosfamide (CIFX) 5 g/m2 given as a 24-hour infusion plus mesna 6 g/m2 during and for 12 hours after the ifosfamide infusion, every 3 weeks for up to six courses. Of 454 patients entered, 438 were eligible and analyzed for response and survival. CIFX had a higher response rate (31.1% v 17.8%, p = .004) and longer progression-free survival (PFS) time (P = .003) compared with cisplatin alone. The median times to progression or death were 4.6 and 3.2 months, respectively. C + M showed no significant improvement in these parameters compared with cisplatin alone. Survival was associated with initial performance score (PS; 0 was more favorable; P < .001) and with age (younger was unfavorable, P = .025). There was no significant difference in overall survival between cisplatin and either of the combinations. Leukopenia, renal toxicity, peripheral neurotoxicity, and CNS toxicity were more frequent with CIFX (P < .05). CIFX improved the response rate and PFS duration in advanced cervix cancer compared with cisplatin alone, but at the cost of greater toxicity and with no improvement in survival.